From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Organic Vaccines Partner with NIH for MERS-CoV Countermeasures

by Global Biodefense Staff
November 19, 2014
Middle East Respiratory Syndrome Coronavirus

MERS coronavirus particles (green) on camel epithelial cells. Credit: NIAID, CSU

Organic Vaccines LLC this week announced it has entered into a commercial evaluation license agreement with the National Institutes of Health (NIH) and a three-year collaborative agreement with the US National Cancer Institute (NCI), with a principal goal of developing human monoclonal antibody-based techniques targeting the Middle East Respiratory Syndrome Coronovirus (MERS-CoV).

The agreements were locked in July and September 2014, respectively.

“These agreements shall enable Organic Vaccines to complement its strategy against MERS CoV. During our meeting of September 18th at the control and command center of the Ministry of Health in Jeddah (Saudi Arabia), we have explained the science and exposed our strategy,” said Patrick Rambaud, President and CEO of Organic Vaccines Plc. Our objective is to be at the earliest in a position to offer a stopgap treatment on a compassionate basis. We have already started complementary studies to meet WHO requirements and submit our dossier.”

Organic Vaccines focuses on the development of preventive and therapeutic vaccines produced using the patient’s own white blood cells. Areas of vaccine development cover children vaccines, flu vaccines and HPV adult vaccines (preventive and therapeutic) as well as the implementation of white blood cell banks.

Source: Organic Vaccines press release, adapted.

From Our Partners
Tags: CoronavirusMERS-CoVNIH

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC